QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文 THORACIC CANCER, 2022 作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo 收藏  |  浏览/下载：32/0  |  提交时间：2022/12/23 checkpoint inhibitor pneumonitis  Chinese experts consensus  immune checkpoint inhibitor-related adverse effects   Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文 THORACIC CANCER, 2022 作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo 收藏  |  浏览/下载：36/0  |  提交时间：2022/12/22 fusion  precision medicine  solid tumor  targeted therapy  tyrosine receptor kinase   A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non-small cell lung cancer (NSCLC). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Zhou, Caicun;  Ren, Shengxiang;  Luo, Yongzhong;  Wang, Lei;  Xiong, Anwen 收藏  |  浏览/下载：16/0  |  提交时间：2022/12/23 Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial 期刊论文 LANCET ONCOLOGY, 2022, 卷号: 23 作者:  Zhou, Qing;  Chen, Ming;  Jiang, Ou;  Pan, Yi;  Hu, Desheng 收藏  |  浏览/下载：104/0  |  提交时间：2022/03/21 Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China 期刊论文 THORACIC CANCER, 2021 作者:  Shi, Yuequan;  Fang, Jian;  Zhou, Chengzhi;  Liu, Anwen;  Wang, Yan 收藏  |  浏览/下载：65/0  |  提交时间：2022/01/25 advanced lung cancer  immune checkpoint inhibitors  immune-related adverse events  real-world data